



Shagufta Shaheen

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm 2238

MC 6560

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 723-8748

Bio

BIO

Dr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Fellowship: Stanford Hospital and Clinics Neuro-Oncology Fellowship CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Fellowship: Loma Linda University Hematology and Medical Oncology Fellowship (2018) CA
- Residency: St Joseph Hospital Internal Medicine Residency (2010) IL
- Medical Education: MGM Medical College (2004) India
- Fellowship, Stanford University , Neuroendocrine Tumor Fellowship (2019)
- Fellowship, Loma Linda University , Hematology and Oncology Fellowship (2018)
- Residency, Saint Joseph University of Illinois at Chicago , Internal Medicine (2010)

- Internship, Government Medical College, Kashmir , Internship (2003)
- Medical Education, MGM Medical College, India , Bachelor of Medicine and Surgery (2002)
- Board Certification, American Board of Internal Medicine , Medical Oncology (2018)
- Board Certification, American Board of Internal Medicine , Internal Medicine (2010)

Research & Scholarship

CLINICAL TRIALS

- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome, Recruiting
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors, Not Recruiting
- Chromogranin A as Blood Marker in Cancer Patients, Not Recruiting
- Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery, Not Recruiting
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors, Not Recruiting
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors, Not Recruiting

Publications

PUBLICATIONS

- **Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR**
Meng, Q., Halfdanarson, T., Bornhorst, J., Jann, H., Shaheen, S., Shi, R., Halperin, D. M.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177Lu-DOTATATE.** *Clinical nuclear medicine*
Somoza, E. A., Duan, H., Shaheen, S., Fischer, G. A., Aparici, C. M.
2022
- **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.** *The oncologist*
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., Mari Aparici, C.
2022
- **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up** *ONCOLOGIST*
Duan, H., Ferri, V., Fisher, G., Shaheen, S., Davidzon, G., Iagaru, A., Aparici, C.
2022
- **Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience**
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., Nguyen, J., Franc, B. L., Iagaru, A., Aparici, C.
LIPPINCOTT WILLIAMS & WILKINS.2022: E42-E43
- **Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX)**
Pollom, E. L., Shelton, A., Fisher, G. A., Bien, J., King, D., Johnson, T., Chen, C., Shaheen, S., Chong, C., Vitzthum, L., Kirilcuk, N., Morris, A. M., Kin, et al
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., Giordano, T., Halfdanarson, T. R., Halperin, et al
2021; 19 (7): 839-868
- **Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan**
Shaheen, S., Gardner, R., Sundaram, V., Hornbacker, K., Moradi, F., Wu, J., Kunz, P.

LIPPINCOTT WILLIAMS & WILKINS.2020: 486

- **Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.** *Current treatment options in oncology*
Shaheen, S. n., Moradi, F. n., Gamino, G. n., Kunz, P. L.
2020; 21 (4): 25
- **Targeted and novel therapy in advanced gastric cancer** *EXPERIMENTAL HEMATOLOGY & ONCOLOGY*
Selim, J. H., Shaheen, S., Sheu, W., Hsueh, C.
2019; 8 (1): 25
- **Concomitant KRAS and BRAF mutations in colorectal cancer** *JOURNAL OF GASTROINTESTINAL ONCOLOGY*
Midthun, L., Shaheen, S., Deisch, J., Senthil, M., Tsai, J., Hsueh, C.
2019; 10 (3): 577–81
- **Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.** *Experimental hematology & oncology*
Shaheen, S., Mirshahidi, H., Nagaraj, G., Hsueh, C. T.
2018; 7: 11
- **Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.** *Journal of chemotherapy (Florence, Italy)*
Guddati, A. K., Shaheen, S.
2013; 25 (3): 184-91
- **Secondary mucosa-associated lymphoid tissue (MALT) lymphoma of the colon.** *Medical oncology (Northwood, London, England)*
Shaheen, S., Guddati, A. K.
2013; 30 (2): 502
- **Gastrointestinal stromal tumor: a rare abdominal tumor.** *Case reports in oncology*
Shaheen, S., Guddati, A. K.
2013; 6 (1): 148-53
- **Uterine leiomyosarcoma manifesting as a tricuspid valve mass.** *Case reports in oncology*
Marak, C. P., Ponea, A. M., Alappan, N., Shaheen, S., Guddati, A. K.
2013; 6 (1): 119-26
- **Extracavitary manifestation of primary effusion lymphoma as a right atrial mass.** *Case reports in oncology*
Marak, C. P., Ponea, A. M., Shim, C., Shaheen, S., Guddati, A. K.
2013; 6 (1): 114-8
- **Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature.** *Cutis*
Selim, A. A., Shaheen, S., Lockshin, N., Khachemoune, A.
2009; 84 (1): 33-8
- **Melanotic neuroectodermal tumor of infancy: review of literature and case report.** *Journal of pediatric surgery*
Selim, H., Shaheen, S., Barakat, K., Selim, A. A.
2008; 43 (6): E25-9